Cftr Trikafta denied as experimental or investigational by CVS Caremark?

Trikafta covered for FDA-labeled mutations + CF center attestation. Symdeko/Orkambi non-preferred when Trikafta-eligible.

CFF 2023 Modulator Recommendations + CFTR2 database for non-F508del responsive variants. April 2023 FDA expansion to age 2-5 (VX20-445-111). Step-therapy through inferior modulator contradicts CFF first-line Trikafta recommendation.

## Why CVS Caremark Denies Trikafta as Experimental

An "experimental or investigational" denial from CVS Caremark typically means the plan's clinical criteria either have not been updated to reflect current FDA approval status, or the specific use being requested (a particular age group, weight category, or mutation type covered by a recent label expansion) has not yet been incorporated into the plan's internal coverage policy. Given that this triple-combination CFTR modulator therapy has received FDA approval and is endorsed by major cystic fibrosis specialty organizations, an experimental denial is one of the most straightforwardly reversible types — particularly at the external review level, where independent reviewers apply current clinical evidence standards rather than potentially outdated internal plan criteria.

## Your Federal Appeal Rights

Experimental or investigational denials are explicitly covered by ACA §2719 external review requirements. Under ERISA §503, employer plans must provide full-and-fair review. You have 180 days from the denial to file an internal appeal and typically four months after an internal denial to request external independent review. Expedited review is available when delay would seriously jeopardize health. External reviewers in experimental-denial cases are required to apply current medical evidence and recognized clinical standards — not just the plan's own criteria.

## The Concrete Appeal Process

1. Obtain the exact basis for the experimental classification — the denial should cite which clinical criterion the plan applied. Request the plan's current clinical coverage policy for CFTR modulators. 2. Pull the current FDA prescribing label (from FDA.gov) and confirm the approval status and approved indications for this patient's mutation profile and age group. 3. File a written internal appeal citing FDA approval status, the date of approval, and the applicable clinical guideline organization's endorsement. 4. If the internal appeal is denied, immediately request external independent review — this is where experimental denials are most often overturned. 5. Attach a prescriber letter summarizing the evidence base as recognized by the Cystic Fibrosis Foundation and other relevant specialty organizations.

## Documentation to Gather

• Current FDA prescribing label downloaded from FDA.gov, with the approval date and applicable indication highlighted
• Confirmed CFTR genotype report confirming the prescribed use falls within the FDA-approved indication
• Prescriber's medical-necessity letter referencing FDA approval, the relevant specialty organization's clinical care guidelines, and the peer-reviewed evidence basis for this therapy class
• Clinical notes documenting diagnosis, genotype, disease severity, and current functional status
• Any FDA label expansion documents relevant to the patient's age group or mutation type, if the plan's criteria predate a recent expansion

## Criteria-Mapping Structure

Obtain CVS Caremark's clinical criteria policy. Then map each experimental-classification criterion:

| Experimental Criterion | Rebuttal Evidence | |---|---| | Not FDA-approved | Current FDA label with approval date | | Not endorsed by recognized specialty organizations | CF Foundation guideline reference | | Inadequate peer-reviewed evidence | Prescriber letter summarizing evidence basis | | Patient characteristic outside studied population | Genotype report + FDA indication language |

External review is strongly recommended if the internal appeal is denied. IRO reviewers consistently overturn experimental denials for drugs with unambiguous FDA approval and broad specialty-society endorsement.